Jeremy Abramson, MD, MMSc
Dr. Abramson is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center, and Associate Professor of Medicine at Harvard Medical School. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School. He completed a residency in Internal Medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson's clinical and research interests are in non-Hodgkin lymphomas, Hodgkin lymphoma, and CLL. His research involves the design and conduct of clinical trials of new cancer therapies and cellular immunotherapies in these diseases.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GenentechTopic:lymphomaDate added:01/16/2024Date updated:01/16/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BMSTopic:lymphomaDate added:01/16/2024Date updated:01/16/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GileadTopic:lymphomaDate added:01/16/2024Date updated:01/16/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:SeagenTopic:lymphomaDate added:01/16/2024Date updated:01/16/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:InteriusTopic:lymphomaDate added:01/16/2024Date updated:01/16/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AbbVieTopic:lymphomaDate added:01/16/2024Date updated:01/16/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BeiGeneTopic:lymphomaDate added:01/16/2024Date updated:01/16/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:LillyTopic:lymphomaDate added:01/16/2024Date updated:01/16/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:CellectarTopic:lymphomaDate added:01/16/2024Date updated:01/16/2024Relationship end date:02/17/2023